Development of IGF-IR inhibitors in pediatric sarcomas

E. Anders Kolb, Richard Gorlick

Research output: Contribution to journalReview articlepeer-review

50 Scopus citations


For approximately two decades, the insulin-like growth factor (IGF) has been implicated in the pathogenesis of numerous pediatric malignancies, including osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma. In the past, major toxicities have limited the clinical development of IGF-targeted therapies. However, recent interest has been heightened by the availability of increasingly specific small molecules and antibodies directed at IGF-I receptor. Preclinical data using these inhibitors against xenograft models of pediatric sarcomas, coupled with responses in adults with Ewing sarcoma, have generated significant excitement about the clinical potential of this class of drugs and have driven the rapid development of numerous clinical trials now under way. This article reviews the preclinical data and the ongoing clinical trials, as well as issues regarding the further development of these drugs specifically for pediatric malignancies.

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalCurrent oncology reports
Issue number4
StatePublished - Jul 2 2009

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Development of IGF-IR inhibitors in pediatric sarcomas'. Together they form a unique fingerprint.

Cite this